E. Consortium Policies and Guidelines
In planning the ICGC, the Scientific Planning Committee recognized the importance of generating a document that would be communicated widely, and contain sufficient information to allow funding agencies and scientists in many countries to make decisions on future participation. Incomplete scientific knowledge (such as tumor heterogeneity for many cancers), rapidly evolving technologies e.g., next generation sequencing technologies, diversity of funding mechanisms, and differences across nations in regards to informed consent and/or sharing of samples across international boundaries are examples of issues that were considered by the committee and its working groups. The approach adopted by the planning teams has been to define a limited number of principles that are central to participation in the project, and provide recommendations to readers based on what is considered “best practices” at the time of writing this document. The authors attempted to discriminate essential from recommended principles using the terms “policy” and “guideline”.
What is a consortium policy?
A consortium policy is a principle which consortium members agree to follow, during the course of the project. Although policies will likely be long-lasting, the ICGC will periodically review its policies. POLICIES are highlighted in grey.
What is a consortium guideline?
Consortium guidelines refer to recommendations made by ICGC working groups that offer advice as to what is believed to constitute “best practices” at a given time. Given the rapid evolution in technologies or new knowledge gleaned from the data generated by ICGC or other groups, it is expected that guidelines will evolve. It is also expected that approaches will need to vary based on tumor types, local laws, or other factors. In such cases, it is expected that ICGC members will be able to compare and explain differences in approaches, relative to ICGC guidelines. The ICGC has chosen to make most of its recommendations as guidelines rather than policies to allow flexibility in approaches and promote innovation. In this document, guidelines are often written in blue-shaded boxes.
In this first document prepared by the ICGC, the authors strived to differentiate recommendations that are policy from those that are guidelines (even if some issues are clearly a mix of both). It is up to individual projects that join the ICGC to declare a clear plan, e.g., samples, criteria for being a sample, exons used, quality control, etc.
Over time, the ICGC will generate best practices documents that will describe the current state-of-the-art, and propose modifications of the guidelines.
- E.1 Informed Consent, Access and Ethical Oversight
- E.2 Data Release Policies
- E.3 Publication Policy
- E.4 Intellectual Property Policy
- E.5 Tumor Types and Subtypes that will be studied by the ICGC
- E.6 Quality Standards of Samples
- E.7 Study Design and Statistical Issues
- E.8 Genome Analyses
- E.9 Data Management
Last Updated on: 7 February 2010